Condition
Primary Focal Segmental Glomerulosclerosis
Total Trials
6
Recruiting
1
Active
1
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
P 2 (5)
Trial Status
Completed4
Not Yet Recruiting1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT06466135Phase 2Recruiting
Study of WAL0921 in Patients With Glomerular Kidney Diseases
NCT04983888Phase 2CompletedPrimary
Obinutuzumab in Primary FSGS
NCT06315504Not Yet Recruiting
Circulating Factors in Nephrotic Syndrome
NCT03422510Phase 2CompletedPrimary
FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)
NCT01573533Phase 2CompletedPrimary
A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
NCT01665391Phase 2CompletedPrimary
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
Showing all 6 trials